Literature DB >> 15611056

Structural diversities of active site in clinical azole-bound forms between sterol 14alpha-demethylases (CYP51s) from human and Mycobacterium tuberculosis.

Koji Matsuura1, Shiro Yoshioka, Takehiko Tosha, Hiroshi Hori, Koichiro Ishimori, Teizo Kitagawa, Isao Morishima, Norio Kagawa, Michael R Waterman.   

Abstract

To gain insights into the molecular basis of the design for the selective azole anti-fungals, we compared the binding properties of azole-based inhibitors for cytochrome P450 sterol 14alpha-demethylase (CYP51) from human (HuCYP51) and Mycobacterium tuberculosis (MtCYP51). Spectroscopic titration of azoles to the CYP51s revealed that HuCYP51 has higher affinity for ketoconazole (KET), an azole derivative that has long lipophilic groups, than MtCYP51, but the affinity for fluconazole (FLU), which is a member of the anti-fungal armamentarium, was lower in HuCYP51. The affinity for 4-phenylimidazole (4-PhIm) to MtCYP51 was quite low compared with that to HuCYP51. In the resonance Raman spectra for HuCYP51, the FLU binding induced only minor spectral changes, whereas the prominent high frequency shift of the bending mode of the heme vinyl group was detected in the KET- or 4-PhIm-bound forms. On the other hand, the bending mode of the heme propionate group for the FLU-bound form of MtCYP51 was shifted to high frequency as found for the KET-bound form, but that for 4-PhIm was shifted to low frequency. The EPR spectra for 4-PhIm-bound MtCYP51 and FLU-bound HuCYP51 gave multiple g values, showing heterogeneous binding of the azoles, whereas the single gx and gz values were observed for other azole-bound forms. Together with the alignment of the amino acid sequence, these spectroscopic differences suggest that the region between the B' and C helices, particularly the hydrophobicity of the C helix, in CYP51s plays primary roles in determining strength of interactions with azoles; this differentiates the binding specificity of azoles to CYP51s.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15611056     DOI: 10.1074/jbc.M413042200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Design of novel antituberculosis compounds using graph-theoretical and substructural approaches.

Authors:  Alejandro Speck Planche; Marcus Tulius Scotti; América García López; Vicente de Paulo Emerenciano; Enrique Molina Pérez; Eugenio Uriarte
Journal:  Mol Divers       Date:  2009-04-02       Impact factor: 2.943

Review 2.  Spectroscopic studies of the cytochrome P450 reaction mechanisms.

Authors:  Piotr J Mak; Ilia G Denisov
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2017-06-28       Impact factor: 3.036

Review 3.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

4.  Spin equilibrium and O₂-binding kinetics of Mycobacterium tuberculosis CYP51 with mutations in the histidine-threonine dyad.

Authors:  Gareth K Jennings; Anuja Modi; Justin E Elenewski; Caroline M Ritchie; Thuy Nguyen; Keith C Ellis; John C Hackett
Journal:  J Inorg Biochem       Date:  2014-04-12       Impact factor: 4.155

Review 5.  Potential drug targets in the Mycobacterium tuberculosis cytochrome P450 system.

Authors:  Paul R Ortiz de Montellano
Journal:  J Inorg Biochem       Date:  2018-01-12       Impact factor: 4.155

6.  Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations.

Authors:  Josh T Pearson; John J Hill; Jennifer Swank; Nina Isoherranen; Kent L Kunze; William M Atkins
Journal:  Biochemistry       Date:  2006-05-23       Impact factor: 3.162

7.  Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv.

Authors:  Kirsty J McLean; Paul Carroll; D Geraint Lewis; Adrian J Dunford; Harriet E Seward; Rajasekhar Neeli; Myles R Cheesman; Laurent Marsollier; Philip Douglas; W Ewen Smith; Ida Rosenkrands; Stewart T Cole; David Leys; Tanya Parish; Andrew W Munro
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

8.  Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections.

Authors:  Galina I Lepesheva; Hee-Won Park; Tatiana Y Hargrove; Benoit Vanhollebeke; Zdzislaw Wawrzak; Joel M Harp; Munirathinam Sundaramoorthy; W David Nes; Etienne Pays; Minu Chaudhuri; Fernando Villalta; Michael R Waterman
Journal:  J Biol Chem       Date:  2009-11-18       Impact factor: 5.157

9.  The use of isomeric testosterone dimers to explore allosteric effects in substrate binding to cytochrome P450 CYP3A4.

Authors:  Ilia G Denisov; Piotr J Mak; Yelena V Grinkova; Dominic Bastien; Gervais Bérubé; Stephen G Sligar; James R Kincaid
Journal:  J Inorg Biochem       Date:  2015-12-31       Impact factor: 4.155

10.  Cloning and characterization of CYP51 from Mycobacterium avium.

Authors:  Michael P Pietila; Pawan K Vohra; Bharati Sanyal; Nancy L Wengenack; Sreekumar Raghavakaimal; Charles F Thomas
Journal:  Am J Respir Cell Mol Biol       Date:  2006-03-16       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.